Research map: Real‐World Outcomes of Radium‐223 Therapy in Metastatic Castration‐Resistant Prostate Cancer: Predictive Value of PSA Doubling Time and Enzalutamide Continuation

Back to the article

Papers in this map

  1. Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer · Chris C. Parker · 2013 · 3413 citations · Cited by this paper
  2. Comprehensive Genomic Characterization Between Urothelial Carcinoma Subtypes/Divergent Differentiation (S/ DD ) and Pure Urothelial Carcinoma Using a Large‐Scale Japanese Genomic Panel Dataset · 2026 · Related
  3. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer · Karim S. Fizazi · 2017 · 2313 citations · Cited by this paper
  4. Cancer‐Associated Fibroblasts Promote Development of Papillary Renal Cell Carcinoma by Inducing Histone Lactylation of RBM15B to Modify in an m6A ‐Dependent Manner on ANLN · 2026 · Related
  5. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer · Ian D. Davis · 2019 · 1651 citations · Cited by this paper
  6. Long‐Term Oncologic Outcomes After Laparoscopic Radical Nephroureterectomy: A Contemporary Analysis From a Japanese Multicenter Cohort · 2026 · Related
  7. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer · Kim N. Chi · 2019 · 1577 citations · Cited by this paper
  8. Diabetes Is an Independent Risk Factor for Radiation‐Induced Hematuria After Robotic Stereotactic Body Radiotherapy for Prostate Cancer · 2026 · Related
  9. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer · Andrew J. Armstrong · 2019 · 1241 citations · Cited by this paper
  10. Artificial Intelligence–Based Objective Evaluation of Nerve‐Sparing Status Combined With Preserved Urethral Length Predicts Urinary Continence Recovery After Robot‐Assisted Radical Prostatectomy · 2026 · Related
  11. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer · Matthew R. Smith · 2022 · 972 citations · Cited by this paper
  12. Efficacy of Testosterone Replacement Therapy Combined With Exercise on Body Composition in Hypogonadal Men · 2026 · Related
  13. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial · Oliver A. Sartor · 2014 · 499 citations · Cited by this paper
  14. Real‐World Occurrence of Adverse Events Associated With Adjuvant Pembrolizumab Therapy for Renal Cell Carcinoma: A Multicenter Retrospective Study · 2026 · Related
  15. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer · Susan Halabi · 2016 · 477 citations · Cited by this paper
  16. Interpreting Sealing‐Device Effects in Retroperitoneal Laparoscopic Adrenalectomy · 2026 · Related
  17. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial · Matthew R. Smith · 2019 · 413 citations · Cited by this paper
  18. Oncological Outcomes and Prognostic Factors of Platinum‐Based Chemotherapy Followed by Avelumab Maintenance Therapy Compared With Platinum‐Based Chemotherapy Alone: A Propensity Score–Matched Analysis in a Real‐World Population · 2026 · Related
  19. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial · Peter Hoskin · 2014 · 409 citations · Cited by this paper
  20. Impact of Absolute PSA Value and Relative PSA Response Rate on Overall Survival in Patients With Metastatic Castration‐Sensitive Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors · 2026 · Related
  21. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial · Fred Saad · 2016 · 295 citations · Cited by this paper
  22. Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial · Nicholas J. Vogelzang · 2016 · 97 citations · Cited by this paper
  23. Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program · Oliver A. Sartor · 2017 · 76 citations · Cited by this paper
  24. Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial · Bertrand F. TOMBAL · 2025 · 50 citations · Cited by this paper
  25. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer · Nobuaki Matsubara · 2017 · 26 citations · Cited by this paper
  26. Dynamic changes of bone metastasis predict bone‐predominant status to benefit from radium‐223 dichloride for patients with castration‐resistant prostate cancer · Kohei Hashimoto · 2020 · 21 citations · Cited by this paper
  27. Real-world safety and effectiveness of radium-223 in Japanese patients with castration-resistant prostate cancer (CRPC) and bone metastasis: exploratory analysis, based on the results of post-marketing surveillance, according to prior chemotherapy status and in patients without concomitant use of second-generation androgen-receptor axis-targeted agents · Hirotsugu Uemura · 2021 · 16 citations · Cited by this paper
  28. Prostate-specific antigen doubling time following radium-223 treatment as a predictor of the clinical course in patients with metastatic castration-resistant prostate cancer · Gen Kawaguchi · 2023 · 8 citations · Cited by this paper
  29. Real-World Treatment Patterns and Survival in Metastatic Castration-resistant Prostate Cancer: A Systematic Review of Observational Studies · Amit D. Raval · 2025 · 3 citations · Cited by this paper
  30. Radium-223 use and survival by line of treatment in metastatic castration-resistant prostate cancer: a nationwide population-based register study · Charlotte Alverbratt · 2025 · 2 citations · Cited by this paper

Source: OpenAlex (CC0)